Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Clinical trial NCT02743546 · WITHDRAWN

Trial details

NCT number: NCT02743546
Sponsor: Janssen Research & Development, LLC
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Follicular Lymphoma, Mantle-Cell

Start date: 2016-07-20
Primary completion: 2018-09-30
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.